PFIZER, MODERNA VACCINES ‘DRAMATICALLY INCREASE’ HEART ATTACK RISK, RENOWNED CARDIOLOGIST WARNS
By Sharyl Attkisson | The Defender
The COVID-19 Pfizer and Moderna mRNA vaccines “dramatically increase” a common measure of heart risk in people.
That’s according to a recently published “warning” in the journal Circulation by cardiologist Dr. Steven Gundry, who is called a pioneer in infant heart transplant surgery.
The analysis was presented at the recent meeting of the American Heart Association.
The “dramatic changes in most patients” mean they are at higher risk of a new acute coronary syndrome, such as a heart attack, according to Gundry.
In part, the analysis states:
“We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.”
Gundry explained:
“Recently, with the advent of the mRNA COVID-19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.”
Thousands of heart-related injuries have been reported following COVID mRNA vaccines. These injuries lead to the formation and progression of cardiac lesions which may become unstable and rupture, leading to cardiac events.
The PULS (Protein Unstable Lesion Signature) test measures the most clinically significant protein biomarkers that leak from cardiac lesions in the blood vessel walls, providing a measure of the body’s immune system response to arterial injury.
Scientists have already established a myriad of heart- and blood-related effects of COVID-19 vaccines in some patients, including young people. Among the adverse events linked to the vaccines are thrombosis blood clots and heart inflammation known as myocarditis and pericarditis.
The Centers for Disease Control and Prevention and the U.S. Food and Drug Administration say the vaccines are safe and effective for everyone they are recommended for, and that the benefits outweigh the known risks, which will be emerging for some years as more people get vaccinated.
Originally published by Sharyl Attkisson.
Sharyl Attkisson
Sharyl Attkisson is a nonpartisan investigative journalist, five-time Emmy Award winner, and recipient of the Edward R. Murrow award for investigative reporting.
Abstract of article by Dr Gundry published in medical journal CIRCULATION 2021;144:A10712, Nov 2021
MRNA COVID VACCINES DRAMATICALLY INCREASE ENDOTHELIAL INFLAMMATORY MARKERS AND ACS RISK AS MEASURED BY THE PULS CARDIAC TEST: A WARNING
By Steven R Gundry
Abstract
Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.
The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.
This report summarizes those results.
A total of 566 patients, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot.
Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac.
These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vaccine.
We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.